CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-17 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +118,418 | $15.85 | $1.9M | 1,623,377 |
| 2025-10-17 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −118,418 | $17.06 | $2.0M | 1,504,959 |
| 2025-10-17 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −118,418 | 0 | ||
| 2025-10-16 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +318,282 | $15.85 | $5.0M | 1,823,241 |
| 2025-10-16 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −318,282 | $17.05 | $5.4M | 1,504,959 |
| 2025-10-16 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −318,282 | 118,418 | ||
| 2025-10-15 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +414,683 | $15.85 | $6.6M | 1,919,642 |
| 2025-10-15 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −414,683 | $16.93 | $7.0M | 1,504,959 |
| 2025-10-15 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −414,683 | 436,700 | ||
| 2025-10-13 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +20,727 | $15.85 | $329K | 1,525,686 |
| 2025-10-13 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −20,727 | $16.25 | $337K | 1,504,959 |
| 2025-10-13 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,727 | 851,383 | ||
| 2025-10-09 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +104,940 | $15.85 | $1.7M | 1,609,899 |
| 2025-10-09 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −104,940 | $16.30 | $1.7M | 1,504,959 |
| 2025-10-09 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −104,940 | 872,110 | ||
| 2025-10-08 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +10,307 | $15.85 | $163K | 1,515,266 |
| 2025-10-08 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +128,295 | $7.45 | $956K | 1,643,561 |
| 2025-10-08 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −138,602 | $16.20 | $2.2M | 1,504,959 |
| 2025-10-08 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,307 | 977,050 | ||
| 2025-10-08 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −128,295 | 0 |
Page 17 of 29 · 570 trades